ADCs	Antibody–Drug Conjugates
ADT	Androgen Deprivation Therapy
AR	Androgen Receptor
ARSIs	Androgen Receptor Signaling Inhibitors
BR	Biochemical Recurrence
CRPC	Castration-Resistant Prostate Cancer
cGA	Glucometabolic Activity
CLI	Cerenkov Luminescence Imaging
CT	Computer Tomography
DDR	DNA Damage Repair
DUPA	Dicarboxy Propyl Ureido Pentanedioic Acid
EC	Electron Capture
FAR	Flexible Autoradiography
FDA	Food and Drug Administration
FOLR1	Folate Receptor α
FR	Folate Receptor
GR	Glutamate Receptor
HTRT	Hyperthermia–Radiation Combined Therapy
LET	Linear Energy Transfer
LDR	Low-dose-rate
mCRPC	Metastatic Castration-Resistant Prostate Cancer
miRNAs	Micro RNAs
NAALDase	N-acetylated Alpha-Linked Acidic Dipeptidase
OS	Overall Survival
PARPi	Poly-ADP-ribose Polymerase Inhibitors
PC	Prostate Cancer
PCSCs	Prostate Cancer Stem Cells
PET	Positron Emission Tomography
PFS	Progression-Free Survival
PRMs	Positive Resection Margins
PSA	Prostate-Specific Antigen
PI3K	Phosphoinositide 3-kinases
RFC	Reduced Folate Carrier
RT	Radionuclide Therapy
SBRT	Stereotactic Body Radiotherapy
SGs	Salivary Glands